Morningstar cut Acrux to “accumulate" from “buy" with a “very high" fair value uncertainty and a $2 fair value price.
The drug delivery company is trialling a range of applications of its patented transdermal drug delivery technology.
Loading...
Elise Shaw writes on Markets specialising in Equity Markets, Commodities, Mining. Based in our Sydney newsroom, Elise has over 25 years experience as a finance and markets journalist and editor. Connect with Elise on Twitter.
